Cosmos Health Inc.

Cosmos Health Inc. is a U.S.-listed healthcare distribution and branded-products company with operations centered in Greece, the UK and other European markets. It wholesales pharmaceuticals and healthcare products, manufactures and markets branded generics and OTC products, and also sells its proprietary Sky Premium Life nutraceutical line through retail and e-commerce channels.

−23,5 %

12,1 %

−29,3 %

+19,9 %

1.00

0.85

— Cosmos Health Inc.
%
Pharmaceutical wholesale and healthcare distribution45% Distribution of prescription drugs, OTC products, medical devices and related healthcare goods to pharmacies and other healthcare buyers.
Branded pharmaceuticals and generics25% Production, promotion and sale of licensed branded generics and OTC products in Europe.
Nutraceuticals15% Proprietary Sky Premium Life supplements sold through retail, e-commerce and distribution partners.
Contract manufacturing and pharma production10% GMP-based manufacturing services and production capacity used for third-party and in-house products.
Digital health and telemedicine5% Direct-to-consumer telemedicine platform and related healthcare services through ZipDoctor.

Cosmos sells primarily to pharmacies, hospitals, private clinics and other pharmaceutical wholesalers that need...

  • Retail pharmaciesprimary

    Buy pharmaceuticals, OTC products and supplements for daily resale and patient demand.

  • Hospitals and private clinicssecondary

    Purchase medicines, medical devices and healthcare consumables for clinical use.

  • Wholesale distributorssecondary

    Source broad product assortments for onward distribution in local markets.

  • Consumer nutraceutical buyerssecondary

    Purchase Sky Premium Life products through Amazon UK and partner channels for wellness use.

  • Telemedicine subscribersemerging

    Use ZipDoctor for affordable 24/7 access to physicians and mental health counselors.

The company’s operating footprint is centered in Greece and the UK, with distribution and manufacturing assets...

  • Greece is the core operating base for distribution and manufacturing
  • The UK is used for Amazon-based consumer nutraceutical sales
  • Europe is the main market for branded generics and OTC products
  • The UAE is an expansion market for Sky Premium Life via Pharmalink
  • Cross-border sales depend on local regulation, logistics and licensing

Cosmos is pursuing a mix of organic growth and acquisitions to expand its distribution network, product portfolio and...

01
Acquisition-led network expansionshort-term

Adds customer bases, distribution routes and scale quickly in fragmented markets.

02
Brand and product expansionmedium-term

Higher-margin proprietary products can improve mix versus pure wholesale.

03
Vertical integration and manufacturingmedium-term

Own manufacturing and GMP capabilities can support margin expansion and control.

04
International channel expansionmedium-term

Broader market access reduces reliance on any single country or channel.

The company has disclosed substantial doubt about its ability to continue as a going concern, making financing access a...

critical

Going concern and liquidity dependence

Management says substantial doubt exists and expects to rely on cash, debt/equity financing or loans.

Scope
Corporate funding and operating continuity
Materiality
high
high

Acquisition integration and synergy realization

Growth depends on integrating acquired networks, systems and customer bases without disrupting service.

Scope
Bikas and other acquired distribution assets
Materiality
high
high

Regulatory and licensing compliance

Pharmaceutical wholesale, GMP manufacturing and cross-border sales require ongoing compliance.

Scope
Greece, UK, EU and UAE operations
Materiality
high
medium

Supply-chain and inventory availability

Wholesale and manufacturing depend on timely sourcing of quality raw materials and finished goods.

Scope
Pharmaceuticals, nutraceuticals and medical devices
Materiality
medium
medium

Foreign exchange and tax complexity

The company operates in multiple currencies and tax jurisdictions, affecting earnings and cash flow.

Scope
Greece, UK and other foreign operations
Materiality
medium
Revenue recognition under ASC 606
Affects quarterly revenue timing and gross margin comparability
Foreign currency translation
Can create volatility in equity and reported earnings
Deferred tax assets and NOL carryforwards
Affects tax expense and realizability of tax assets
Acquired intangibles and customer bases
Potential impairment charges if synergies do not materialize

: 28/04/2026